Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis

Biological Trace Element Research

Volumn 132, Issue 1-3, 2009, Pages 35-40

  Zanoni, Lourdes Zélia ^a,c   Brustoloni, Yvone Maia ^a   Melnikov, Petr ^a   Cônsolo, Carlos Eduardo Z ^b  

^a FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^b University for the Development of the State and the Region of Pantanal   (Brazil)

^c Campus Universitário ^*  (Brazil)

Author keywords

Antimony; Children; ECG alterations; Visceral leishmaniasis

Indexed keywords

MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; EXTRASYSTOLE; FEMALE; HEART FUNCTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; P WAVE; PR INTERVAL; PRESCHOOL CHILD; QRS COMPLEX; QT PROLONGATION; SCHOOL CHILD; SINUS RHYTHM; T WAVE AMPLITUDE; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ANTIMONY; ANTIPROTOZOAL AGENTS; CARDIOVASCULAR ABNORMALITIES; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFANT; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 72349083125     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12011-009-8387-9     Document Type: Article

References (16)

1. State Department of Health of Mato Grosso do Sul. Information and Notification System Diseases. Internal newsletter. August, 2006.
2. WL Roberts WJ McMurray PM Rainey 1998 Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime) Antimicrob Agents Chemother 42 1076 1082 1:CAS:528:DyaK1cXislWltLg%3D 9593130
3. MA Santos RC Marques CA Farias DM Vasconcelos JM Stewart DL Costa, et al. 2002 Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis Rev Soc Bras Med Trop 35 629 633 12612746
4. Yan S, Jin L, Sun H (2005) Antimony in Medicine. In Gielen M, Tiekink ERT Metallotherapeutic drugs and Metal-bases diagnostic agents. The use of metals in medicine. John Wiley & Sons. Chichester. p. 443-446
5. MA Tirmenstein PI Plews CV Walker MD Woolery HE Wey MA Toraason 1995 Antimony-induced oxidative stress and toxicity in cultured cardiac myocytes Toxicol Appl Pharmacol 130 41 47 10.1006/taap.1995.1006 1:CAS:528: DyaK2MXjtFOmsLg%3D 7839369
6. LM Volkova AS Kanischeva AA Udovenko YN Milhailov VI Vovna 1983 The problem of shortened Sb-Sb distances and polynuclear groups in the compounds of trivalent antimony Coord Chem 5 609 615
7. JD Chulay L Fleckenstein DH Smith 1988 Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate Trans R Soc trop Med Hyg 82 69 72 10.1016/0035-9203(88) 90267-2 1:STN:280:DyaL1M%2FitVensQ%3D%3D 2845611 (Pubitemid 18056241)
8. ACR Saldanha GAS Romero C Guerra E Merchan-Hamann VO Macedo 2000 Estudo comparativo entre estibogluconato de sódio BP 88® e antimoniato de meglumina no tratamento da leishmaniose cutânea II. Toxicidade bioquímica e cardíaca Rev Soc Bras Med Trop 33 383 388 10.1590/S0037-86822000000400009 1:STN:280:DC%2BD3cvnsVKqsA%3D%3D 10936953
9. ALP Ribeiro JB Drummond AC Volpini AC Andrade VMA Passos 1999 Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumina Braz J Med Biol Res 32 297 301 10.1590/S0100-879X1999000300008 1:CAS:528:DyaK1MXisFaju7s%3D 10347787
10. NC Hepburn J Nolan L Fenn RM Herd JM Neilson GR Sutherland, et al. 1994 Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies QJM 87 465 472 1:STN:280:DyaK2M%2Fgs1Kjsw%3D%3D 7922300
11. JD Chulay HC Spencer M Mugambi 1985 Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate) Am J Trop Med Hyg 34 702 709 1:STN:280:DyaL2M3ns12hsw%3D%3D 2992303
12. YA Kuryshev L Wang BA Wible X Wan E Ficker 2006 Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents Mol Pharmacol 69 1216 1225 10.1124/mol.105.019281 1:CAS:528:DC%2BD28XjtlKnt7k%3D 16418337
13. SN Hatem T Sweeten V Vetter M Morad 1995 Evidence for presence of Ca2+ channel-gated Ca2+ stores in neonatal human atrial myocytes Am J Physiol 268 1195 1201
14. A Cruz PM Rainey BL Herwaldt G Stagni R Palacios R Trujillo, et al. 2007 Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate J Infect Dis 195 602 608 10.1086/510860 1:CAS:528:DC%2BD2sXitlOrsLs%3D 17230422 (Pubitemid 46214405)
15. CP Thakur GP Sinha AK Pandey N Kumar P Kumar SM Hassan, et al. 1998 Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases Ann Trop Med Parasitol 92 561 569 10.1080/00034989859258 1:CAS:528:DyaK1cXlslWltbk%3D 9797829 (Pubitemid 28365366)
16. N Berhe Y Abraham A Hailu A Ali G Mengistu K Tsige, et al. 2001 Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis East Afr Med J 78 608 610 1:STN:280: DC%2BD38vmtFCrsQ%3D%3D 12219968